There is no antiviral drug that eliminates HPV from your body the way antibiotics clear a bacterial infection. Treatment for HPV in women targets what the virus causes, whether that is genital warts, abnormal cervical cells, or precancerous lesions, rather than the virus itself. Most HPV infections clear without any intervention at all, typically within one to two years. When the infection does lead to changes that need attention, the options range from simple monitoring to outpatient surgical procedures, and the choice depends heavily on the severity of what your doctor finds.
Most HPV Infections Resolve Without Treatment
HPV is extremely common after becoming sexually active, but the majority of infections cause no symptoms and no lasting harm. The immune system clears most HPV infections within 12 to 24 months, and clearance is especially common in younger women.1PubMed. The natural history of human papillomavirus infection This is why a positive HPV test does not automatically mean you need treatment. It often means you need closer monitoring so that if the infection persists and begins causing cellular changes, those changes are caught early.
Certain factors can slow your body’s ability to clear the virus. Smoking is one of the most studied. Research following women over time found that current smokers were roughly half as likely to clear an HPV infection as non-smokers, and the effect was dose-dependent: the longer, more frequently, and more heavily a woman smoked, the lower her chances of clearing the infection.2PubMed Central. Impact of smoking exposure on human papillomavirus clearance among Chinese women: A follow-up propensity score matching study Immune suppression from other causes, such as HIV or immunosuppressive medications, also delays clearance. If you have been told you have a persistent HPV infection, quitting smoking is one of the few concrete steps you can take to help your body do its job.
When Low-Grade Changes Mean Watching and Waiting
If a Pap smear or HPV test leads to a colposcopy and biopsy, the results might come back showing low-grade squamous intraepithelial lesions, often called CIN1. These are mild cellular changes in the cervix. For most women, CIN1 does not progress to anything dangerous. A large Italian study following women with CIN1 for up to five years found that only about 7% progressed to high-grade lesions.3BMJ Open. Long-term observational approach in women with histological diagnosis of cervical low-grade squamous intraepithelial lesion: an Italian multicentric retrospective cohort study The standard approach is continued surveillance rather than immediate treatment. If high-risk HPV is still present at a follow-up visit around two years later, your doctor may then recommend excisional treatment rather than continued waiting.
The logic behind this conservative approach is straightforward: treating something that would have resolved on its own subjects you to a surgical procedure with real, if small, risks. But if the infection persists and cells continue to change, the calculus shifts toward intervention. Your screening schedule and your doctor’s recommendations will reflect where you fall on that spectrum.
Treating High-Grade Cervical Lesions
High-grade lesions, typically classified as CIN2 or CIN3, are precancerous. Left unmonitored, they carry a meaningful risk of progressing to cervical cancer over years to decades. Treatment at this stage is standard practice, and the goal is to remove or destroy the abnormal tissue before it can become invasive.
The most common procedures are:
- LEEP (or LLETZ): A thin electrified wire loop shaves off the abnormal tissue from the cervix. It is the most widely used excisional procedure, performed under local anesthesia in a clinic or office. Recovery is usually a few weeks, with some cramping and discharge.
- Cold knife conization (CKC): A surgical scalpel removes a cone-shaped piece of cervical tissue. CKC is typically done under general or regional anesthesia and removes a deeper cone of tissue than LEEP.
- Cryotherapy: A probe freezes and destroys the abnormal cells. This is simpler and cheaper than excisional methods and does not require electricity, making it especially important in lower-resource settings.
- Thermal ablation: A heated probe destroys the abnormal tissue. It works similarly to cryotherapy in terms of simplicity but does not require the gas canisters that cryotherapy depends on.
A meta-analysis comparing LEEP and CKC found no significant differences in recurrence rates, positive surgical margins, residual disease, or complications like secondary bleeding and cervical narrowing. The main practical difference was that CKC produced a significantly deeper cone specimen.4PubMed Central. Meta-analysis of cold-knife conization versus loop electrosurgical excision procedure for cervical intraepithelial neoplasia In other words, LEEP and CKC are about equally effective, but CKC is a larger operation. LEEP is generally preferred when either would do.
Ablative methods like cryotherapy and thermal ablation destroy tissue in place rather than removing it, which means there is no specimen to send to a pathologist. This is a tradeoff: ablation is simpler and cheaper, but your doctor cannot verify clear margins. A randomized trial comparing cryotherapy, thermal ablation, and LEEP for cervical precancer found treatment success rates in the range of 60 to 67% across all three, with no statistically significant differences between them.5The Lancet Oncology. Efficacy of thermal ablation versus cryotherapy for cervical intraepithelial neoplasia: a randomised controlled trial Thermal ablation did cause less pain during the procedure than cryotherapy: about 61% of women in the thermal ablation group reported cramping compared with 75% in the cryotherapy group.6PubMed Central. A Prospective Randomized Trial to Compare Safety, Acceptability and Efficacy of Thermal Ablation and Cryotherapy in a Screen and Treat Setting
A separate systematic review reported recurrence rates of about 5% at 12 months after cryotherapy or LEEP, compared with roughly 1.4% after CKC. Complications were more common after CKC, including a higher risk of premature delivery in future pregnancies, though that risk also exists to a lesser degree after LEEP and cryotherapy.7International Journal of Gynecology & Obstetrics. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia
Treating Genital Warts
Genital warts are caused by low-risk HPV types, almost always types 6 and 11, that are different from the high-risk types linked to cancer. Warts are not dangerous but they can be uncomfortable, cosmetically distressing, and persistent. Treatment aims to remove the visible warts, though none of the available methods eliminate the underlying HPV infection. Recurrence is common regardless of the method used.
Cryotherapy with liquid nitrogen is one of the most effective clinic-based treatments. In one trial, repeated cryotherapy sessions cleared warts completely in about 86% of patients.8PubMed. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid Trichloroacetic acid (TCA), a chemical applied directly to the wart, is another option but cleared warts in a smaller proportion of patients in the same study and caused ulceration at the application site more often. A separate trial found the two methods more comparable, with clearance in about 81% of TCA-treated patients versus 88% for cryotherapy, though early recurrence was similar at roughly 36 to 39%.9Sexually Transmitted Infections. Cryotherapy compared with trichloroacetic acid in treating genital warts
Patient-applied options include imiquimod cream, which stimulates the local immune response, and sinecatechins ointment, a botanical extract derived from green tea. Both require weeks of regular home application. These are convenient alternatives when you prefer not to make repeated clinic visits, but they tend to work more slowly. Your doctor will recommend a method based on the number, size, and location of the warts, as well as your preferences.
How Cervical Treatment Affects Future Pregnancies
One of the first questions many women have after hearing they need a LEEP or cone biopsy is whether it will affect their ability to get pregnant or carry a pregnancy to term. The short answer is that fertility itself does not appear to be compromised, but there is a measurable increase in the risk of preterm delivery.
A meta-analysis found that LEEP was associated with about a 60% higher risk of preterm birth before 37 weeks compared with women who had never had the procedure.10PubMed Central. Loop Electrosurgical Excision Procedure and Risk of Preterm Birth: A Systematic Review and Meta-analysis However, when LEEP-treated women were compared specifically with women who had cervical dysplasia but did not undergo excision, the increased risk essentially disappeared. That suggests the underlying condition, not just the procedure, may contribute to the higher preterm birth rate. A separate study found no link between the specific characteristics of the LEEP, including the depth of tissue removed, and the rate of preterm delivery.11Obstetrics & Gynecology. The Effect of Loop Electrosurgical Excision Procedure on Future Pregnancy Outcome
If you are planning a pregnancy after a cervical excision, let your obstetrician know. They may monitor your cervical length more closely during pregnancy. The overall message is reassuring: the vast majority of women who have had a LEEP go on to have healthy, full-term pregnancies.
HPV Vaccination After Treatment Reduces Recurrence
You might assume the HPV vaccine is only useful before you have been exposed to the virus. Increasingly, evidence shows that getting vaccinated after treatment for cervical precancer significantly reduces the chance of the disease coming back. A recent meta-analysis pooling data from multiple studies found that HPV vaccination after conization was associated with a 62% reduction in recurrence of high-grade lesions.12PubMed Central. Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins The benefit held regardless of which vaccine was used and whether margins were clear or positive.
Individual studies have shown similar patterns. In one, recurrence of high-grade lesions was about 3.3% in vaccinated women compared with nearly 14% in unvaccinated women.13PubMed Central. Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution’s Experience Another large study found recurrence in 2.5% of the vaccinated group versus 7.2% of the unvaccinated group, and multivariate analysis identified skipping vaccination after LEEP as an independent risk factor for recurrence.14PubMed. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?
The mechanism appears to be primarily prophylactic: the vaccine protects against reinfection or reactivation of the same HPV types rather than clearing an existing active infection.12PubMed Central. Impact of HPV vaccine on CIN2+ recurrence after conization: a systematic review and meta-analysis of vaccination timing, valency and surgical margins If you have been treated for high-grade cervical disease and have not been vaccinated, this is worth discussing with your doctor.
Topical Treatments Being Studied for Cervical Lesions
Researchers have been exploring whether topical medications applied directly to the cervix could treat high-grade lesions without surgery. The appeal is obvious: avoiding a procedure that removes cervical tissue would eliminate the associated risks to future pregnancies.
Imiquimod, already used for genital warts, has been tested for cervical lesions. In a randomized trial comparing imiquimod to LEEP for high-grade lesions, about 63% of women in the imiquimod group had histologic regression, meaning the abnormal cells improved or disappeared. Complete remission was seen in 37%. However, HPV clearance at six months was lower with imiquimod (43%) than with LEEP (64%).15PubMed. Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial A small feasibility study tested a combination of 5-fluorouracil and imiquimod applied to the cervix, with histologic regression in roughly 91% of participants who completed at least half of the prescribed doses.16PubMed Central. Feasibility of 5-Fluorouracil and Imiquimod for the Topical Treatment of Cervical Intraepithelial Neoplasias (CIN) 2/3 These results are early-stage and not yet strong enough to displace surgery as the standard, but they represent a genuinely promising direction for women who want to preserve cervical tissue.
Supplements and Complementary Approaches
You will find no shortage of online claims about supplements that “cure” HPV. Most of these are unsupported. One exception with actual clinical trial data is AHCC, a mushroom-derived extract. A randomized, placebo-controlled trial found that about 64% of women taking AHCC cleared a persistent HPV infection after six months, compared with roughly 11% on placebo.17PubMed Central. AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections Among placebo patients who later switched to AHCC, half cleared the infection within six months. These are striking numbers, but this was a single trial with a small sample. The results need replication before AHCC could be considered a reliable treatment.
General immune-supportive measures, including adequate sleep, exercise, a nutrient-dense diet, and not smoking, are reasonable steps. They are not specific HPV treatments, but given that your immune system is the primary mechanism through which HPV is cleared, supporting it makes practical sense.
Screening and Follow-Up After Treatment
Treatment for cervical precancer is not a one-and-done event. Follow-up surveillance matters because recurrence, while uncommon, is possible. After a LEEP or other excisional procedure, you will typically have HPV testing and cytology at regular intervals for several years. The U.S. Preventive Services Task Force recommends that women aged 30 to 65 screen every three years with cytology alone, every five years with high-risk HPV testing alone, or every five years with both tests combined.18U.S. Preventive Services Task Force. Cervical Cancer: Screening After treatment for a high-grade lesion, your follow-up schedule will be more frequent than routine screening, often starting at six months post-procedure and continuing annually for several years before returning to the standard interval.
Self-sampling for HPV, done at home with a vaginal swab kit, is being studied as a way to improve follow-up compliance. One advantage is convenience: women who struggle to attend clinic appointments could mail in a sample instead. However, a study in a high-income setting found that about 17% of women did not return their self-sampling kit, and 90% of those who missed their in-person follow-up also failed to send back their self-collected sample.19Preventive Medicine Reports. HPV self-sampling in the follow-up of women after treatment of cervical intra-epithelial neoplasia: A prospective study in a high-income country Self-sampling may work best as a complement to clinic visits rather than a replacement, especially for women already disengaged from care. The broader concept of home-based follow-up is still worth developing, because the women who most need monitoring are sometimes the hardest to reach.20PubMed Central. Self-sampling for high-risk human papillomavirus as a follow-up alternative after treatment of high-grade cervical intraepithelial neoplasia
The Emotional Weight of an HPV Diagnosis
The physical side of HPV treatment gets most of the attention, but the psychological impact of a positive result can be significant, and it is undertreated. Qualitative research consistently finds that women who test positive for high-risk HPV experience anxiety, stigma, and stress tied to the sexually transmitted nature of the infection and its association with cancer.21PubMed Central. Social and psychological impact of HPV testing in cervical screening: a qualitative study Many women describe feeling dirty or ashamed, even when they intellectually understand that HPV is nearly universal.
Disclosure to sexual partners is a particular source of distress. A systematic review found that women worried about being perceived as promiscuous, feared rejection, and in some cases ended relationships preemptively rather than face a conversation about HPV.22BMJ Sexual & Reproductive Health. Concerns about disclosing a high-risk cervical human papillomavirus (HPV) infection to a sexual partner: a systematic review and thematic synthesis The severity of the emotional response was shaped by how well women understood HPV: those who did not realize how common it is or that most infections resolve tended to experience more distress.23PubMed Central. Exploring the psychosexual impact and disclosure experiences of women testing positive for high-risk cervical human papillomavirus If you are struggling with the emotional fallout, knowing that the vast majority of sexually active adults will have HPV at some point, and that most will clear it, is not just a platitude. It is the epidemiological reality.
Therapeutic Vaccines on the Horizon
Preventive HPV vaccines like Gardasil 9 stop new infections from taking hold. They do not treat an infection you already have. An entirely different class of vaccines, called therapeutic HPV vaccines, is in development. These aim to train the immune system to recognize and attack cells already infected with HPV, specifically cells expressing the viral proteins E6 and E7 that drive cancer development.
Across 17 clinical trials reviewed in the literature, several platforms have shown promise. DNA-based vaccines like VGX-3100 achieved HPV clearance in up to 78% of responders in phase II studies when delivered with electroporation, a technique that uses brief electrical pulses to help cells absorb the vaccine. Viral-vector vaccines and peptide-based formulations have also demonstrated immune responses and lesion regression, though with more variability depending on the specific vaccine and the grade of the lesion being treated.24PubMed Central. Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials
An mRNA-based therapeutic HPV vaccine has shown strong results in animal models, with tumor suppression persisting months after immunization and early immunogenicity data in primates supporting a move toward human trials.25PubMed. mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization None of these therapeutic vaccines are approved for clinical use yet, and the jump from promising phase II data to a reliable, widely available treatment is large. But the pace of development is real, and within the next decade it is plausible that women with persistent high-risk HPV will have a non-surgical option to clear the infection before it ever reaches the point of needing a LEEP.
Treatment Access in Lower-Resource Settings
Much of the global burden of cervical cancer falls on low- and middle-income countries where LEEP equipment, trained specialists, and pathology labs are scarce. In these settings, a “screen and treat” approach, where women who test positive for HPV are treated immediately with cryotherapy or thermal ablation rather than being referred for further diagnostic workup, is an accepted strategy. It leads to some overtreatment, since not every HPV-positive woman has precancerous lesions, but in places where patients are unlikely to return for a second visit, treating on the spot prevents more cancers than a perfect diagnostic pathway that half of women never complete.26Cancer Epidemiology, Biomarkers & Prevention. Overtreatment and Cost-Effectiveness of the See-and-Treat Strategy for Managing Cervical Precancer
Cost differences between treatment methods are substantial. In a South African trial among HIV-positive women, cryotherapy cost about $118 per patient compared with roughly $163 for LEEP, and the gap widened further when measured per case cured.27PLOS ONE. Costs and cost-effectiveness of LEEP versus cryotherapy for treating cervical dysplasia among HIV-positive women in Johannesburg, South Africa Modeling studies in Papua New Guinea have found that even once-lifetime HPV self-collection screening with immediate treatment is highly cost-effective at local economic thresholds.28BMJ. Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea The tools to prevent cervical cancer exist; the challenge is getting them to the women who need them most.